CSCIED

期刊目次

加入编委

期刊订阅

添加您的邮件地址以接收即将发行期刊数据:

Open Access Article

International Journal of Clinical Research. 2023; 7: (5) ; 114-116 ; DOI: 10.12208/j.ijcr.20230234.

Efficacy of rosuvastatin and atorvastatin in the treatment of elderly coronary heart disease
瑞舒伐他汀与阿托伐他汀治疗老年冠心病效果

作者: 傅海霞 *

山东省淄博市临淄区皇城中心卫生院 山东淄博

*通讯作者: 傅海霞,单位:山东省淄博市临淄区皇城中心卫生院 山东淄博;

发布时间: 2023-05-23 总浏览量: 343

摘要

目的 探讨在冠心病老年患者治疗中应用瑞舒伐他汀和阿托伐他汀,对疗效的影响。方法 试验者是2021年1月至2023年1月在医院治疗的80例冠心病老年患者,以随机信封法分为对照组与观察组,每组的例数均为40例,对照组采取阿托伐他汀,观察组采取瑞舒伐他汀,比对两组临床疗效与血脂水平。结果 观察组总疗效率高于对照组,P<0.05;观察组血脂水平低于对照组,P<0.05。结论 以瑞舒伐他汀治疗,可缓解患者症状,进一步增强疗效的同时,还能起到降低患者体内血脂水平的作用,临床借鉴价值较高。

关键词: 冠心病;老年;阿托伐他汀;瑞舒伐他汀;疗效;血脂水平

Abstract

Objective: To investigate the effect of rosuvastatin and atorvastatin in the treatment of elderly patients with coronary heart disease (CHD).
Methods: The subjects were 80 elderly patients with coronary heart disease treated in hospital from 2021.01 to 2023.01. They were divided into control group and observation group by random envelope method, with 40 cases in each group. Atorvastatin was taken in the control group and rosuvastatin was taken in the observation group, and the clinical efficacy and lipid levels of the two groups were compared.
Results: The total therapeutic efficiency of the observation group was higher than that of the control group (P<0.05); The blood lipid level in the observation group was lower than that in the control group (P<0.05); The indexes of cardiac function in the observation group were better than those in the control group (P<0.05); The quality of life in the observation group was higher than that in the control group (P<0.05).
Conclusion  : Rosuvastatin treatment can relieve the symptoms of patients, further enhance the curative effect, but also play a role in reducing the blood lipid level of patients, which is of high clinical reference value.

Key words: Coronary heart disease; Old age; Atorvastatin; Resuvastatin; Efficacy; Blood lipid level

参考文献 References

[1] 刘高,文相华,黎霞. 瑞舒伐他汀和阿托伐他汀治疗冠心病的效果比较[J]. 中国医学创新,2022,19(35):145-149.

[2] 孙恒. 瑞舒伐他汀与阿托伐他汀治疗冠心病的效果及安全性探讨[J]. 中国现代药物应用,2022, 16(19): 117-119.

[3] 张金龙. 瑞舒伐他汀与阿托伐他汀治疗冠心病的临床效果比较[J]. 临床合理用药杂志,2022,15(11):61-63.

[4] 郑坤,彭丽丽,徐卅卅. 瑞舒伐他汀与阿托伐他汀在冠心病患者治疗中的应用效果比较[J]. 临床合理用药杂志,2022,15(06):38-40.

[5] 刘娜. 瑞舒伐他汀与阿托伐他汀治疗冠心病的疗效及对血脂、hs-CRP、Hcy水平的影响[J]. 中国现代药物应用,2022,16(04):146-148.

[6] 付琪,陈入菲,范蒲迎. 瑞舒伐他汀与阿托伐他汀治疗老年冠心病患者临床疗效对比分析[J]. 贵州医药,2021, 45(12): 1896-1897.

[7] 洪霞,浦锡娟,钟为辉. 冠心病患者应用瑞舒伐他汀与阿托伐他汀治疗的药学效果对比[J]. 中国医药指南,2021, 19(22):30-32.

[8] 牛建雄,杨晓艳. 比较瑞舒伐他汀、阿托伐他汀治疗冠心病患者的疗效与安全性[J]. 世界复合医学,2021,7(03): 192-194.

[9] 高文阔,陈淑静. 冠心病患者行瑞舒伐他汀与阿托伐他汀治疗的临床疗效对比研究[J]. 中外医疗,2021,40(02): 106-108.

[10] 郑龙辉. 瑞舒伐他汀与阿托伐他汀治疗冠心病患者的疗效对比研究[J]. 心血管病防治知识,2020,10(31): 37-39.

引用本文

傅海霞, 瑞舒伐他汀与阿托伐他汀治疗老年冠心病效果[J]. 国际临床研究杂志, 2023; 7: (5) : 114-116.